Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
about
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.Investigational immunotherapeutics for B-cell malignancies.
P2860
Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
@en
type
label
Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
@en
prefLabel
Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
@en
P2860
P1433
P1476
Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
@en
P2093
P2860
P304
P356
10.3109/10428199509112195
P577
1995-11-01T00:00:00Z